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Abstract
Background:  Recent advances in genomics, proteomics, and the increasing demands for
biomarker validation studies have catalyzed changes in the landscape of cancer research, fueling the
development of tissue banks for translational research. A result of this transformation is the need
for sufficient quantities of clinically annotated and well-characterized biospecimens to support the
growing needs of the cancer research community. Clinical annotation allows samples to be better
matched to the research question at hand and ensures that experimental results are better
understood and can be verified. To facilitate and standardize such annotation in bio-repositories,
we have combined three accepted and complementary sets of data standards: the College of
American Pathologists (CAP) Cancer Checklists, the protocols recommended by the Association
of Directors of Anatomic and Surgical Pathology (ADASP) for pathology data, and the North
American Association of Central Cancer Registry (NAACCR) elements for epidemiology, therapy
and follow-up data. Combining these approaches creates a set of International Standards
Organization (ISO) – compliant Common Data Elements (CDEs) for the mesothelioma tissue
banking initiative supported by the National Institute for Occupational Safety and Health (NIOSH)
of the Center for Disease Control and Prevention (CDC).
Methods: The purpose of the project is to develop a core set of data elements for annotating
mesothelioma specimens, following standards established by the CAP checklist, ADASP cancer
protocols, and the NAACCR elements. We have associated these elements with modeling
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architecture to enhance both syntactic and semantic interoperability. The system has a Java-based
multi-tiered architecture based on Unified Modeling Language (UML).
Results: Common Data Elements were developed using controlled vocabulary, ontology and
semantic modeling methodology. The CDEs for each case are of different types: demographic,
epidemiologic data, clinical history, pathology data including block level annotation, and follow-up
data including treatment, recurrence and vital status. The end result of such an effort would
eventually provide an increased sample set to the researchers, and makes the system interoperable
between institutions.
Conclusion: The CAP, ADASP and the NAACCR elements represent widely established data
elements that are utilized in many cancer centers. Herein, we have shown these representations
can be combined and formalized to create a core set of annotations for banked mesothelioma
specimens. Because these data elements are collected as part of the normal workflow of a medical
center, data sets developed on the basis of these elements can be easily implemented and
maintained.
Background
The tremendous amount of development in molecular
and systems biology driven by advancement in transla-
tional medicine and the increasing demands for biomar-
ker validation studies have helped to catalyze the path to
personalized medicine. To make these promises a reality,
researchers from various basic sciences as well as clinical
disciplines are realizing the need for biospecimens with
high-quality clinical annotation. This need has led to the
development of controlled vocabularies in order to gener-
ate a robust system of clinical annotation that will allow
samples to be better matched to the research queries at
hand and experimental results to be better understood
and more easily verified. Additionally, this standardiza-
tion allows comparative research, data-sharing and in-
depth analysis of data among institutions [1,2]. The gen-
eral consensus that the recommendation in the RAND
Corporation's Case Studies of Existing Human Tissue
Repositories, that ".... the collection of consistent and
high-quality data associated with every biospecimen and
employing a standardized set of common data elements
[for annotation]..." is now broadly considered best prac-
tice reflects the need for such standardization [3].
The concept of tissue banking and the informatics infra-
structure coupled with it has emerged as a successful strat-
egy to support clinical and translational research. The
need for controlled vocabularies in medical computing
systems is widely recognized. Even systems dealing with
narrative text and images provide enhanced capabilities
through coding of their data using controlled vocabularies
and ontology with semantic interoperability. Develop-
ment of Common Data Elements (CDEs) involves the cre-
ation of a distinct readable phrase or sentence associated
with a data element within a data dictionary. Utilization
of CDEs then helps to describe and extract meaning or
semantics from that data element. And finally, collection
of CDEs in a uniform manner across multiple institutions
allows data sharing in a standardized fashion [4,5].
Over the past decade, oncologists, researchers and bioin-
formaticians began to articulate some of these require-
ments by devising systems to develop CDEs with the help
of ad hoc sets of controlled terms for use in their local
applications. Subsequently, well-characterized data ele-
ments were created and established by the National Can-
cer Institutes initiatives such as the Cooperative Breast
Cancer Tissue Resource (CBCTR) [6,7], Cooperative Pros-
tate Cancer Tissue Resource (CPCTR) [8-11] and the Can-
cer Biomedical Informatics Grid (caBIG) [12]. In a
statewide effort, we have accomplished this standardiza-
tion in the Pennsylvania Cancer Alliance Bioinformatics
Consortium (PCABC) [13].
In April of 2006 the National Institute for Occupational
Safety and Health (NIOSH) of the Center for Disease Con-
trol and Prevention (CDC) recognized the need for an
effort to create a repository of human mesothelioma
biospecimen. It issued an RFA to collect large numbers of
fresh as well as archival pleural, pericardial and peritoneal
mesothelioma tissue specimens along with blood and
DNA samples with associated epidemiologic, pathologic,
genotypic and follow-up data [14]. In September 2006,
the University of Pittsburgh School of Medicine was
awarded funds to develop a national mesothelioma tissue
bank (Mesothelioma Virtual Bank for Translational
Research or MVB) (Grant #: 1U19OH009077-01) [15].
The primary goal of this initiative is to integrate multimo-
dal data from various clinical, pathologic and molecular
systems into an architecture which is supported by a set of
common data elements in order to facilitate basic science,
clinical and translational research. These systems are
designed to facilitate semantic and syntactic interoperabil-
ity in the development of data elements using controlledBMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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vocabulary and ontology in order to make the data under-
standable and shareable for end-users. During the initial
phase of this project, the basic components and standards
developed by CBCTR, CPCTR, PCABC, and cancer Data
Standard Repository (caDSR) model of caBIG were uti-
lized [6-13,16].
The process of developing CDEs typically engages many
individuals and it can take several months to reach con-
sensus among those involved. In the case of MVB a group
of thoracic surgeons, mesothelioma-focused translational
researchers, oncologists, thoracic pathologists, epidemiol-
ogists, cancer registrars, and data managers from various
centers as well as our MVB Research Evaluation Panel
(REP) provided input and approved changes in the CDEs
as they were developed. In this process it was essential to
1) include experts from multiple disciplines, 2) consider
the works of others who had created similar CDEs, and 3)
consider established standards when available. Herein we
describe the process of developing the CDEs and believe
this model is scalable to other organ specific tissue bank-
ing efforts for translational research.
Methods
Participating Institution
Current participating institutions in the MVB include the
Universities of Pennsylvania, Pittsburgh and New York
University (NYU). Also supporting this effort are the Mes-
othelioma Applied Research Foundation (MARF), and a
newly awarded P01 grant to Dr. Michele Carbone (Uni-
versity of Hawaii) that includes members of the MVBs
REP: Dr. Brooke Mossman (University of Vermont), Dr.
Joseph Testa (Fox Chase Cancer Center) and Dr. Harvey
Pass (NYU). Other participants will be added to the con-
sortium as the program expands.
Honest Broker Concept and Human Subject Protection
The MVB uses decentralized sample and data collection
and storage. Every case is assigned a de-identified MVB
number. All specimens are collected using a standardized
Institutional Review Board (IRB)-approved protocol
(Please refer to Additional file 1) and measures are taken
to ensure that proper confidentiality and privacy of
human subjects is maintained with approval by the Insti-
tutional Review Board (IRB) of each participating institu-
tion. The only linkage to the patient identity is retained
locally within the institution, and there are no links con-
necting records to patients. In addition, queries of pub-
licly available websites generate de-identified datasets for
the research community [the so-called "safe harbor"
approach to HIPPA (the Health Insurance Portability and
Accountability Act)-compliance] [17]. Age range rather
than specific dates, are provided instead of the dates of
birth and of diagnosis to meet HIPPA compliant require-
ments and still provide adequate data for most research
purposes. Additionally, the Honest Broker Service devel-
oped by the University of Pittsburgh ensures compliance
of the MVB with specific regulatory agency guidelines for
the release of Protected Health Information (PHI), includ-
ing those of the Office of Human Research Protection
(OHRP) of the Department of Health and Human Serv-
ices (HHS), HIPAA, and the University of Pittsburgh Med-
ical Center (UPMC)/University of Pittsburgh Institutional
Review Board (IRB) [17]. UPMC and the University of
Pittsburgh facilitated the process for developing honest
broker services, and the Department of Biomedical Infor-
matics took the initiative in developing the first, cross-
divisional, collaborative broker service. IRB approval for
the UPMC/University of Pittsburgh honest broker service
was attained on May 8, 2003 (IRB Approval # HB015)
(Please refer to Additional files 2 and 3) [18]. Oversight
for the service is provided by the Director of the Registry
Research Information Service, and all honest brokers are
certified in accordance with UPMC and University of
Pittsburgh IRB policy. HB015 is used as the "gold-stand-
ard" model by the UPMC/University of Pittsburgh IRB.
Various types of data requests are generated, including
those for hospital operational statistics (clinical and qual-
ity improvement, marketing, process improvement, and
incidence reports), research preparation (review of PHI or
aggregate data only for the purpose of preparing a research
hypothesis and protocol), and non-human subjects
research (whereby all PHIs are de-identified prior to use
by the researcher), and research involving human subjects
(requires full-IRB approval). The exempt research classifi-
cation designates circumstances deemed by the IRB to be
excused from research authorization, such as the use of
de-identified health information or limited data sets
(modified "Safe Harbor" permitting state, city, full zip
code, and dates) provided by a certified honest broker,
and research limited to deceased patients.
All data requests are tracked in a secure, web-based data
request tool, regardless of whether the purpose is clinical
or research-related. This tool provides the capability of
measuring trends in Registry use and other data sources,
and serves as the mechanism for assuring compliance
with IRB policies through tracking of broker certification
and IRB-approved/exempt projects. De-identification of
PHI can be done manually by the honest broker by strip-
ping the HIPAA-identified PHI and replacing with a
unique code for each case, or through use of automated
de-identification applications. Unique codes associated
with each record must be maintained on a project-specific
basis by the designated honest brokers. Full de-identifica-
tion of electronic text-based documents for research
projects are referred to the Center for Clinical Research
Information Services (CRIS).BMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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Clinical Research Information Services is a jointly spon-
sored service of the University of Pittsburgh Office of Clin-
ical Research and the Department for Biomedical
Informatics, and a certified honest broker with the Univer-
sity of Pittsburgh IRB possessing a business associate
agreement with UPMC (our health system). CRIS uses the
De-ID© application developed by the Department for Bio-
medical Informatics at the University of Pittsburgh and
licensed by the University of Pittsburgh to De-ID Data
Corp, Philadelphia, PA. The De-ID application is also
used by the National Cancer Institute and other academic
medical centers for various research applications. The
application uses a set of heuristics to identify the presence
of any of the HIPAA-specific identifiers within electroni-
cally stored medical text. Though configurable for either
Safe-Harbor or Limited Data Sets, the disadvantage of
applying De-ID© is the removal of a small amount of clin-
ical information during the de-identification process. A
linkage file stored in an encrypted format is created when
a dataset is processed. The study identifier is a two-part
code: part one is the number of the report for that patient,
and part two is a unique 12 alphanumeric code for that
patient. The major advantage of using De-ID© is that the
study id remains consistent across data sets and different
admissions and/or multiple reports can be easily identi-
fied. In addition, the output generated by De-ID© is briefly
reviewed prior to releasing it to the investigator.
Organization of the Resource
The MVB is governed by a Coordinating Committee that
has handed over responsibilities to several subcommittees
(pathology, epidemiology and cancer registry). Various
sub-committees that are involved in the CDE develop-
ment are illustrated in Figure 1. The Coordinating Com-
mittee includes the principal investigators (PIs), members
of the REP, patient advocates, database coordinators, and
data managers that review request for tissues and data by
end-users. The Committee's main function is to manage
and supervise all of the activities of the MVB. In addition,
the Committee's role in developing the CDEs was to deter-
mine the types of biospecimens (i.e. paraffin archival tis-
sue, tissue microarrays, frozen tissue, etc.) the
biospecimen resource will provide.
The major role of the pathology and epidemiology sub-
committees was to develop standard evaluation guide-
lines and propose pathology-, epidemiology-, and
genotype-specific CDEs related to the different types of
biospecimens collected. Similarly, the cancer registry team
is involved in evaluation of follow-up and outcome-
related CDEs.
The data manager sub-committee includes data managers
from each of three member institutions and database
coordinators. This sub-committee's main role is to imple-
ment and evaluate the CDEs, perform quality assurance
checks on the data collected at each member institution,
and to help coordinate the distribution of tissue requests
and the associated data sets.
Development of the Common Data Elements
With leadership and supervision of the Coordinating
Committee and the domain experts from the subcommit-
tees, the CDE subcommittee was established in order to
develop CDEs (demographics, epidemiology, pathology-
specimen as well as block level annotation, genotype, fol-
low-up and outcome) pertinent to pleural, pericardial,
and peritoneal mesotheliomas (Figure 2). The CDE sub-
committee utilized the experiences of the CBCTR [6,7],
CPCTR [8-11], caBIG [12], PCABC [13], Cooperative
Human Tissue Network (CHTN) [19] Early Diagnosis
Research Network (EDRN) [20], Cancer Family Registries
(CFR) [21], and Specialized Programs of Research Excel-
lence (SPOREs) [22] when developing the CDEs. As stated
earlier, the major standards used to formulate the CDEs
include the NAACCR Data Standards for Cancer Registries
[23], CAP Cancer Protocol and Checklist [24], the ADASP
[25] and the American Joint Committee on Cancer
(AJCC) Cancer Staging Manual [26]. Usage of these data
standards, protocols, checklists and guidelines to develop
CDEs provides a common conceptual model that already
exists between multiple otherwise non-interoperable sys-
tems. The existence of such a conceptual model/frame-
work is sufficient to achieve both syntactic and semantic
interoperability in CDE development.
MVB Organization of the Resource Figure 1
MVB Organization of the Resource. The Coordinating 
Committee determines the types of biospecimens in the 
repository. The Research Evaluation Panel (REP) is the com-
mittee in consultation with the Coordinating Committee. 
The sub-committees for Pathology, Epidemiology, Genotype 
(Molecular), Cancer Registry data and data managers coordi-
nate each other to develop the CDEs for different types of 
biospecimens that MVB has collected.BMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
Page 5 of 18
(page number not for citation purposes)
NAACCR and UPMC Network Registry Network
The core elements and data standards set forth by the
North American Association of Central Cancer Registry
(NAACCR) were utilized to devise the demographic, epi-
demiologic, therapeutic, and outcome-related CDEs as
well as easing the eventual data acquisition for the Bank.
The NAACCR was first established in 1987 as a collabora-
tive umbrella organization for cancer registries, govern-
mental agencies, professional associations, and private
groups in North America interested in enhancing the
MVB CDE categories Figure 2
MVB CDE categories. Five principal categories of CDEs with their attributes and the sub-data types collected. Detail 
description of each CDE under these five main categories can be found in the MVB CDE data dictionary.BMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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quality and use of cancer registry data [22]. It is a profes-
sional organization that develops and promotes uniform
data standards for cancer registration; provides education
and training; certifies population-based registries; aggre-
gates and publishes data from central cancer registries;
and promotes the use of cancer surveillance data and sys-
tems for cancer control and epidemiologic research, pub-
lic health programs, and patient care to reduce the burden
of cancer in North America. All central cancer registries in
the United States and Canada are members. Additionally,
it works to achieve consensus on cancer registration stand-
ards among the many standard setters in the United States
and Canada. These include the American College of Sur-
geons (ACoS), the National Cancer Institute (NCI), and
the Canadian Cancer Registry (CCR) at Statistics Canada.
Today nearly all registries throughout the United States
and Canada have adopted the NAACCR consensus stand-
ards. These standards are updated annually. Maintaining
current standards to meet the needs of the NAACCR com-
munity is an ongoing and major NAACCR activity. The
principal goals of NAACCR include definition of data
standards for cancer registration for use by central regis-
tries, hospital-based registries, and other groups in North
America in order to provide a comprehensive reference to
ensure uniform data collection that reduces the need for
redundant coding and data recording between agencies
and facilitates the collection of comparable data among
groups. It also provides a resource document to help reg-
istries that are establishing or revising their databases and
encourages the adoption of these standards by all parties.
The NAACCR coordinates the implementation of stand-
ards to promote continuity in data collection, exchange,
and analysis. Furthermore the agency helps in improving
and maximizing dissemination, interpretation, and use of
data.
Our Registry Information Services (RIS) is an emerging
division of the UPMC Network Cancer Registry and the
UPMC Cancer Centers [27]. The full-time staff is respon-
sible for maintaining a standardized data system designed
for the collection, management and analysis of specific
patient information. The RIS collects data about demo-
graphics, medical history, diagnostic findings, cancer
grading, treatment, outcomes, and American Joint Com-
mission on Cancer (AJCC TNM) and Surveillance, Epide-
miology and End Results (SEER) cancer staging. This
information is used for administrative planning, educa-
tion, results reporting and research for the University of
Pittsburgh Cancer Institute and UPMC Cancer Centers
[27]. Two distinct sub-divisions operate within the 12
hospital-based registries, 5 stand-alone clinics, and 28
physician offices comprising the UPMC Network Cancer
Registry. One handles data collection and dissemination
for clinical and hospital operational purposes, while the
other is dedicated to the specific efforts and data needs of
the research community of the Centers of Excellence
within the UPMC Cancer Centers and University of Pitts-
burgh Cancer Institute (UPCI). Standardized data is cap-
tured for all reportable diagnoses in accordance with the
Commonwealth of Pennsylvania's Department of Health
regulations, permitting this registry process to be exempt
from HIPAA patient consenting processes. Additionally,
the majority of facilities within the Registry adhere to the
voluntary standards set forth by the American College of
Surgeons Commission on Cancer for approved cancer
programs. It is also a key source for Honest Broker Services
established in May 2003 to meet the needs of our oncol-
ogy research environment.
Primary sources for data extraction include both paper
and electronic medical records. Data is abstracted via
manual and electronic methods into the cancer registry
database by Certified Cancer Registrars (Figure 3). The
entire UPMC Network Cancer Registry information sys-
tem is based on the architecture of the NAACCR consensus
standards, which were realized from standards previously
set by American College of Surgeons, the National Cancer
Institute, and the Canadian Cancer Registry at Statistics
Canada. Updated annually, these data standards allow
meaningful comparison of data across different registries,
and compilation of case-specific information into useful
and meaningful registries thanks to standardized case def-
initions, coding practices and conversions of medical ter-
minology.
CAP Protocol and ADASP guidelines
The core elements and data standards set forth by the Col-
lege of American Pathologists (CAP) and the Association
of Directors of Anatomic and Surgical Pathology (ADASP)
were utilized to devise the pathology CDEs for MVB
resource. In recent years, these two societies (ADASP and
CAP) [25,24,28] have published guidelines for the report-
ing of human malignancies in order to standardize
pathology reporting in an optimal way to ensure that the
information necessary for diagnosis, management, prog-
nostic and predictive factor assessment is available and
understandable. The CAP assigned multidisciplinary
groups of pathologists, surgeons, and radiation and med-
ical oncologists to develop the protocols. Other patholo-
gists and clinicians then reviewed them. After the initial
reviews, the protocols were then further reviewed by mul-
tiple CAP committees and finally approved by its Board of
Governors. The ADASP, in contrast, chose a pathologist
expert in each field to assemble a group from within the
pathology community (with clinician input if desired) to
write specific cancer protocols. These were then approved
by the ADASP council and subsequently by the member-
ship. Even though both societies began the process at
approximately the same time, the streamlined approachBMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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MVB Registry Data Fields Figure 3
MVB Registry Data Fields. The critical registry data fields are divided into two categories: 1) Required fields, which are 
essential and must be entered into the database for a case to be accepted. 2) Conditional required fields, which must be filled 
out when respective biospecimen is entered into the database.BMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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adopted by the ADASP enabled it to publish years earlier
in pathology journals frequented by anatomic patholo-
gists. Although the formats are somewhat different, the
contents are essentially the same.
Recently, the American College of Surgeons Commission
on Cancer (COC) decided to require elements deemed as
essential by the CAP to be described in all pathology
reports in accredited cancer centers as of January 2004.
The COC accredits cancer centers in the United States. It is
important to note that COC does not require that the spe-
cific CAP protocols or synoptic reports be used. ADASP
has updated all of its protocols to comply with the COC
requirements in the form of 37 uniform checklists,
whereas CAP cancer checklists consist of a series of report-
ing guidelines for diagnostic surgical pathology reports for
45 important human cancers. The checklists use the stag-
ing criteria cited in the American Joint Committee on
Cancer staging manual [25] but include a variety of other
references listed in each of the checklists. Moreover, the
checklists are formatted for ease of use. They may be used
as templates for uniform reporting and are designed to be
compatible with voice-activated transcription. The differ-
ent elements in these revised ADASP diagnostic checklists
have been divided into required and optional. The term
required in this context only signifies compliance with the
COC guidelines. ADASP realizes that specimens and prac-
tices vary and that it will not be possible to report these
elements in every case. However, ADASP hopes that
pathologists will find these checklists useful in daily clin-
ical practice, while facilitating compliance with the new
COC requirements. The checklists are in standard PDF file
format, may be easily downloaded from the ADASP, and
are not to be reproduced, altered, or used for commercial
purposes without consent from ADASP [25].
The CAP cancer protocols and checklists and ADASP
guidelines are important reporting standard in pathology,
a field for which no complete electronic data standard is
currently available. Each guideline consists of [1] a check-
list specifying the data elements of the specimen and
tumor that should be included in the diagnostic pathol-
ogy report as well as the valid values that these data ele-
ments may take (Figure 4), and [2] a detailed protocol
providing definitions and further information about the
scientific basis for assessing these variables. Each protocol
and checklist was developed by a separate panel of sub-
specialty experts for that organ system, often representing
differing schools of thought. In each case, expert panels
reviewed the existing literature to determine which fea-
tures provided the most important data for clinical deci-
sion-making. In addition to specifying the data elements
and valid values, these guidelines provide other useful
information for creating structured metadata; the paper
standard [1] logically groups data elements together by
surgical procedures or type of examination (macroscopic
vs. microscopic), [2] distinguishes between required data
elements for which there is unequivocal scientific evi-
dence of their value, and optional data elements which do
not meet that scientific threshold, and [3] maintains rele-
vance with revised versions published as new data
becomes available regarding prognostic factors and clini-
cal outcomes. However, a common data standard which
permits interchange among clinical and research systems
is still urgently needed to advance tissue-based research.
Genotype CDEs
Data related to metabolic gene polymorphisms is availa-
ble for a subset of the cases. These include glutathione S-
transferase M1 (GSTM1), glutathione S-transferase T1
(GSTTM1), cytochrome P450 1A1 (CYP1A1), N-acetyl-
transferase 2 (NAT2), and microsomal epoxide hydrolase
(mEH) gene polymorphisms. The coding of genotype var-
iants follow the standardized procedure previously
described by Garte et al [29].
Fragment of CAP cancer checklist and ADASP guidelines for  reporting mesothelioma Figure 4
Fragment of CAP cancer checklist and ADASP 
guidelines for reporting mesothelioma. Fragment of 
CAP cancer checklist and ADASP guidelines for mes-
othelioma showing relationships between the Data Elements 
with their value domains. Checklist text reproduced with 
permission of the College of American Pathologists and 
Association of Directors of Anatomic and Surgical Pathology.BMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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Usage of these data standards, protocols, checklists and
guidelines to develop CDEs provide a common concep-
tual model that already exists between multiple non-inter-
operable systems. The existence of such a conceptual
model is necessary to achieve either syntactic or semantic
interoperability in CDE development.
Creating information models for CDEs with the aid of 
Unified Modeling Language
Information models provide an abstract formal represen-
tation of the conceptual or physical entities. Information
models for the MVB biorepository are constructed as UML
class diagrams. The UML is a non-proprietary language for
constructing, visualizing, and documenting the artifacts of
software engineering. A UML class diagram is one kind of
diagram that depicts a collection of static model elements
such as physical or conceptual entities and their relation-
ships [30].
To explain, in a UML-class diagram specific conceptual
entities are represented by classes. Each class  may have
attributes that describe specific characteristics of these enti-
ties. Attributes, in turn have one or multiple values. In
many cases, permissible values within a value domain
represent reasons why particular values were absent, for
example because the attribute was not identified or
because the attribute could not be evaluated in this con-
text. In these cases, we segregated 'missing value reasons'
from the value domain proper, creating a separate
attribute name (Figure 5). Classes are related to other
classes by relationships, which are represented by arcs
between classes in the UML diagram. Associations  are
"peer-to-peer" relationships between classes. The names
and cardinality of the ends of the associations are marked
near the boxes that delimit the classes. Other associative
relationships include aggregations and compositions, which
are used to model "whole/part" relationships between
classes.  Generalization  relationships model inheritance
between classes. The class that is generalization of a con-
cept is referred to as the superclass and the class that is spe-
cialization of a generic concept is referred to as the
subclass. Subclasses inherit attributes and methods from
their superclasses. Enumerations  are UML stereotyped
classes that provide a list of named values.
We have used Enterprise Architect (EA) as the UML mod-
eling tool for this project due to its low cost and high per-
formance [31]. During modeling, each UML class,
attribute and enumeration value was annotated with a
human readable definition of the semantic meaning of
that class or attribute. These definitions were created as
tagged values in UML, which provides a method for add-
Fragment of the UML information model for Mesothelioma Figure 5
Fragment of the UML information model for Mesothelioma. Fragment of the CAP checklist, ADASP elements, and 
NAACCR elements UML class model showing association and generalization relationships of MesotheliomaBMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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ing additional information to a UML stereotype. Models
annotated with these definitions were then saved in the
XML Metadata Interchange (XMI) format for further
processing [32].
Semantic metadata based on the ISO/IEC standard
Semantic interoperability requires that the meaning of the
data within the system or analytic services performed by
the system is unambiguous. It must be interpretable by
both humans and computers. In order to achieve this – a
great deal must be known about the meaning and form of
the data. Semantic metadata provides the 'data about data'
needed to interpret the meaning and form of data and to
determine the relationship of one datum to another.
Therefore, semantic metadata must have a common, uni-
form structure, and must be universally available for
inspection, discovery and inference [32].
The basic representation used for semantic metadata
within MVB is defined by ISO/IEC – a standard for meta-
data structure and registration. This specification was
developed for the specific purpose of facilitating world-
wide metadata standardization by providing guidance on
the framework itself, the classification of data, the seman-
tic structure of data, formulation of definitions, naming
and identification, and guidance and instruction of the
registration of metadata [33].
Data elements that conform to ISO/IEC must be associated
with one data element concept (DEC) and one value domain.
The DEC defines the meaning of the datum. Each DEC
must have one and only one object class that describes the
real world or conceptual entity and one and only one prop-
erty that describes some characteristic of that entity. Both
object classes and properties may also take one or more
qualifiers that modify the meaning of the object class or
property. The value domain represents the set of permissible
values that are valid for this datum. Value domains are
annotated with representation terms that classify the data
element according to the category of data stored in the
data element (e.g. indicator, code, number). Value
domains may be either enumerated (e.g. as a set of valid
values) or non-enumerated (e.g. as a number or character
string). Data elements may be aggregated together as clas-
sification scheme items belonging to a classification scheme,
which provides a method for grouping data elements into
a logical hierarchical framework.
Creating basic UML structure
High-level UML classes were then joined by relations rep-
resenting the logical relationships between classes. Associ-
ative relationships were assigned directionality and
cardinality. Inheritance relationships were used to extend
the general classes as each specific CAP cancer checklist
was developed. For example, MesotheliomaNegativeSur-
gicalMargin expresses the surgical margin findings specific
to negative margins in cases of pleural mesothelioma. It is
a subclass of the more general SurgicalMargin, and thus
inherits all of the attributes of SurgicalMargin. Mesotheli-
omaNegativeSurgicalMargin also has additional attributes
that are specific to negative margins. A fragment of the
total UML model is shown in Figure 5.
An important aspect of this phase of creating the model
for CDEs was to determine where generalization relation-
ships should be structurally aligned. Semantic interopera-
bility requires unambiguous semantics. One difficulty in
utilizing a multi-structure modeling environment is that
apparent conflicts may arise when the structures conflict.
This conflict could potentially produce significant ambi-
guity.
Metadata or data descriptors are then developed to
describe a specific CDE. Metadata offers the potential for
true interoperability between systems on two levels: syn-
tactic interoperability, which concerns itself with the abil-
ity to exchange information; and semantic
interoperability, which is the ability to understand and
use the information once it is received. Metadata also has
two components: attributes and valid values. Addition-
ally, ISO/IEC standard for metadata formulation specifies
that metadata should have a qualified name or identifier,
an authority who registers the name, a versioning history
(allowing for modifications), a language or origin, a state-
ment relating to usage, a data typing statement, and a def-
inition that is unambiguous [4,33]. The MVB data
dictionary describing each of the common data elements
were generated by following the ISO/IEC standard for
metadata (Please refer to Additional files 4 and 5).
Development of the MVB database: Informatics 
Architecture and Integration Issues
The MVB Project required a mechanism for making Mes-
othelioma cases searchable via a web interface. The Uni-
versity of Pittsburgh project team met this requirement
using the MVB Query Tool; a web-based application that
is based on the caTISSUE Clinical Annotation Engine
(CAE) System [34]. The resulting system has been made
available publicly on the Department of Biomedical Infor-
matics (DBMI) website [35].
caTISSUE CAE was originally developed by the University
of Pittsburgh as part of the National Cancer Institute's
(NCI) Cancer Biomedical Grid (caBIG) program [34].
This is a toolkit for clinical annotation of biospecimens
for translational research. It is envisioned as an annota-
tion system for the TBPT Workspace by providing stand-
ards-based annotations and tools for integrating data
from existing clinical and research systems. The CAE pro-
vides for manual annotation of biospecimens withBMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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pathology, tumor marker, staging, grading and follow-up
data utilizing a web-based user interface, import of struc-
tured data from clinical information systems such as Ana-
tomic Pathology Laboratory Information Systems
(APLIS), Clinical Pathology Laboratory Information Sys-
tems (CPLIS), and other specimen registries which may be
employed in the life cycle of clinical trials or clinical
research, and integration of annotations from multiple
sources within the translational research center (Figure 6)
It provides a mechanism for entering, importing and
searching for biospecimen annotation. In the latest
released version of this software, clinical annotations are
attached to either a participant/patient, a tissue accession
or to a specimen (part) or sub-specimen (block). Taken
together these entities form a hierarchy or backbone that
encapsulates all of the annotation data for a case. Annota-
tions can be entered manually using the provided user
interface or imported using an XML format.
The CAE system is based on a model-driven architecture.
A UML class model is created using a UML model. The
resulting model is used to generate the source code for
domain classes and the required metadata. The annota-
tion engine uses the domain classes and metadata to
render data entry, query and result screens and to specify
the XML import formats. The latest version of the CAE
software includes models for eight different types of can-
cers: breast, prostate, melanoma, kidney, lung, pancreas,
colon, rectum and central nervous system tumors and is
available.
The various components of CAE include web-tier, busi-
ness tier, data tier and integration tier (Figure 7). The web
tier serves up static HTML, images, style sheets and
dynamically generated web pages via a standard JSP/Serv-
let engine. Dynamic requests will be managed through a
Model-View-Controller (MVC) mechanism. This mecha-
nism manages the processing of individual requests and
the flow between requests. The Spring Framework is being
evaluated for this purpose. The controller object makes
requests to the business tier that results in the return of
model objects that represent the information that must be
presented back to the user. Based upon the result of the
controller actions, the model objects are forwarded to an
appropriate view (JSP) which renders them into a display-
able page. The business tier consists of a set of functional
components, an Object-Relational (O/R) mapping mech-
anism, a metadata interrogation mechanism, a caCORE-
compliant Application Programming Interface (API) and
a set of shared services. These components act together to
implement the principal functionality of the system. The
functional components consist of a series of service
objects that provide a consistent interface to web tier con-
trollers. There are three primary functions such as
"Query", "Manual Annotation" and "Import Manage-
ment". The object layer of the business tier consists of
services the services required for managing domain
objects. The principal functions of this layer are to provide
O/R mapping capabilities via caCORE SDK generated and
custom code. The resulting objects present a unified
model-based interface of the domain to the functional
components so that they need not be concerned with the
physical database implementation. In addition to the O/
R mapping capabilities, the object layer also provides an
API into the domain objects as required by the caBIG sil-
ver-level compliance specification. This API is generated
using the caCORE SDK. Metadata interrogation capabili-
ties can also be accessible from the object layer. The
required metadata are accessible via the caDSR. However,
there may be some additional metadata necessary for the
rendering of user interface components that is applica-
tion-specific. This tier also provides shared services for
logging and audit capabilities, authentication and author-
izations services via the NCI Common Security Module
(CSM) and caDSR access via the NCI Clinical Infrastruc-
ture Application Framework (CIAF) module. The services
will be implemented generically so as to potentially be
reusable by other caBIG™ components. The data tier con-
sists of domain database that houses the clinical annota-
tions data, the security data (users, groups, roles,
protected elements, etc.) and a staging area for import
data. The database is in Oracle with a MySQL implemen-
tation.
The integration tier integrates with caTISSUE CAE in one
of the following two ways:
Overview of caTISSUE Clinical Annotation Engine depicting  data import, integration and query interface in a web-based  environment Figure 6
Overview of caTISSUE Clinical Annotation Engine depicting 
data import, integration and query interface in a web-based 
environment. caTIES is a tool to extract important informa-
tion on archival surgical pathology report and caTISSUE core 
is an enterprise biospecimen repository.BMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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Data import
Anatomic Pathology Lab Information Systems, Cancer
Registries, caTIES and other systems that hold tissue-
related data can add cases or annotation data to the sys-
tem by exporting their data into a published, XML-based
format. The data can then be imported into the annota-
tions database using the web-based import management
capabilities provided by the CAE system (Figure 8).
Application Programming Interface (API)
The CAE system also provides a caBIG™ – compliant API
for accessing domain-object data, which can be utilized by
caTISSUE Core and other future caBIG™-compliant sys-
tems to access and search on annotations data directly.
Currently we are developing version 2.0 of the CAE sys-
tem. This new version of the tool will provide improve-
ments along two primary fronts. First and foremost, while
the 1.X versions of the tool supported only the base hier-
archy of Participant->Accession->Specimen->Sub-speci-
men, version 2.0 will support the annotation of any
network of related entities. The entity types and their rela-
tionship are specified in a UML model and generated
along with the annotations. The CAE system has been
adapted to handle the model that it is given. Secondly, the
specification and management of metadata within the
systems has been enhanced, giving researchers and bioin-
formaticians greater flexibility over the format of the
attributes and items displayed on the user interface.
The MVB Query Tool is developed based upon an early
release of CAE 2.0. The CAE team has developed this
Data import from Anatomic Pathology Laboratory Informa- tion System to the caTISSUE Clinical Annotation Engine web  interface Figure 8
Data import from Anatomic Pathology Laboratory Informa-
tion System to the caTISSUE Clinical Annotation Engine web 
interface.
The overall architecture and tiers of caTISSUE Clinical Annotation Engine Figure 7
The overall architecture and tiers of caTISSUE Clinical Annotation Engine.BMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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release "from the bottom up": i.e., the database and data
management tiers and the API (Application Programming
Interface) to these tiers are complete. The CAE 2.0 API
uses the underlying data tier to provide a mechanism for
performing queries on an annotated network of related
entities. Additionally, the MVB query tool includes a cus-
tom built user-interface that calls upon the API to perform
queries and renders the results.
The entity model that is the basis of the MVB Query Tool
is illustrated in Figure 9, 10, 11. This model has replaced
the strict hierarchy that is at the foundation of the previ-
ous version of CAE. The new model includes constructs
for more explicitly representing disease, treatment and
outcome data. The MVB Query Tool provides a user inter-
face for querying for specimens or cases based upon
attributes of or annotations attached to any of these enti-
ties.
Evaluation of CDEs by respective domain experts
The evaluation phase of the CDEs is an ongoing effort that
allows for the examination of the quality of MVB data col-
lected by the respective Domain Experts, Coordinating




Archival specimens from biopsies and resection from
1981 to present were identified from the pathology
records. At the time of compilation of this manuscript,
there are over 400 annotated cases of pleural, peritoneal
and pericardial mesothelioma specimens that are availa-
ble to the research community. The majority of these cases
consist of archival paraffin blocks from surgical patients
treated between 1981 and 2006, including one paraffin
tissue microarray (TMA). The TMA has been designed to
facilitate identification of markers differentially expressed
in primary mesotheliomas and metastatic lesions. Sam-
ples from 41 patients have been incorporated in the TMA
(Please refer Additional file 6 for the details of the TMA).
The Resource has also accrued DNA and blood samples in
136 cases with clinical annotation. The entire workflow of
Tissue Bank Workflow for MVB across the institutions is
illustrated in Additional files 7 and 8.
Development of the Common Data Elements
With guidance from the Research Evaluation Panel and
the Coordinating Committee, the CDE subcommittee was
primarily involved in the development of CDEs for demo-
graphics, epidemiology and clinical history. These
Detailed view of a queried case on the caTISSUE Clinical  Annotation Engine Query result interface for Mesothelioma  Virtual Bank Figure 10
Detailed view of a queried case on the caTISSUE Clinical 
Annotation Engine Query result interface for Mesothelioma 
Virtual Bank.
The caTISSUE Clinical Annotation Engine Query interface for  Mesothelioma Virtual Bank Figure 9
The caTISSUE Clinical Annotation Engine Query interface for 
Mesothelioma Virtual Bank.BMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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included specimen-level annotation describing the overall
case where a bio-specimen was collected, block-level
annotation which records information on individual
pieces or sections of the bio-specimen banked, and fol-
low-up information about treatment, vital status, and
clinical recurrence.
Development of metadata for CDEs
Metadata is additional data developed to describe a spe-
cific CDE by following the ISO standard, which specifies
that metadata should have a qualified name or identifier,
an authority who registers the name, a versioning history
(allowing for modifications), a language or origin, a state-
ment relating to usage, a data typing statement, and a def-
inition that is unambiguous. The MVB data dictionary
describes each of the common data elements generated by
following the ISO standard for meta-data. The most cur-
rent version of the CDE data dictionary and the data col-
lection template can be accessed at the MVB public
database (Please refer to Additional file 4).
Semantic interoperability of the system
Most tissue bank databases which contain clinical data
generally lack the ability to exchange information in a
common format (syntactic interoperability), the ability to
understand and use the information once it is received by
other systems (semantic interoperability). Another prob-
lem is the panoply of ways that similar or identical con-
cepts or data are described by different users even within
the same institution as well as across institutions. For
example, a data element called "grade of tumor" can be
collected using various formats (e.g. some collect "grade-
1, grade-2, and grade-3" vs. others who collect "low grade,
intermediate grade, and high grade"). Such inconsistency
in data descriptors makes it nearly impossible to aggregate
and manage even modest-sized data sets in order to per-
form basic queries. As a result, these systems are neither
uniform nor flexible. They are incapable of performing
exchange or sharing of information as unambiguous
interpretation of the information is not possible without
semantic and syntactic interoperability.
The MVB database is based on an informatics model that
aids in developing and conveying the semantic interoper-
ability by describing the common data elements in the
form of metadata or data descriptors (about the content,
quality, condition, and other characteristics of the data)
and by using a controlled vocabulary and ontology in
order to make the data understandable and sharable for
end-users. Each common data element is associated with
an object or concept, attribute, and valid value(s). For
example, "patient age at diagnosis" is the CDE that is
made up of "patient" (object), "age at diagnosis" (prop-
erty) and the representation (value domain) in "years".
Specifically for each of the approved CDEs, the data col-
lectors need to know: 1) the fundamental definition of the
data element (i.e., date of diagnosis), 2) how that data ele-
ment will be collected (e.g. 11/2003 vs. Nov. 2003 vs. 11/
03, etc), 3) what are the consensus acceptable values or
codes are for the data element (e.g., precise date of birth,
not calculated from clinical records where the "patient
appears to be a well developed 75 year old"), and 4) what
the acceptable data format is for inclusion into the central
database (e.g., dates as integers not character strings).
Although the concept of formalized metadata is fairly
straightforward, it has rarely been incorporated by clinical
and research groups building translational research data-
bases [13,16].
The CDEs developed by the MVB are ISO/IEC compliant
(International Standards Organization/the International
Electrotechnical Commission) [32]. The MVB defines a
number of fields and relationships for metadata registries
including a detailed metamodel for defining and register-
ing items, of which the primary component is a data ele-
ment. By taking this approach, greater flexibility will be
given to individual institutions than with the current lim-
itations placed in data collection methods and work flow.
As another example, for the CDE "Patient race", the object
is "patient"; the property is "race" and the valid values are
a list of character strings ("Caucasian", "African Ameri-
Detailed view page of a queried case on the caTISSUE Clini- cal Annotation Engine Query result interface for Mesotheli- oma Virtual Bank Figure 11
Detailed view page of a queried case on the caTISSUE Clini-
cal Annotation Engine Query result interface for Mesotheli-
oma Virtual Bank.BMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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can", and "Asian", among others). If legacy databases
from one institution use "African American" and another
institute uses "Black" as a valid value for the "race" field
and both their CDEs and metadata are properly mapped
to the central database, then when researchers query for
"African American" cases in the user interface, the result
would display the total cases ("African American" plus
"black") available from both institutions, because both
terminologies are semantically integrated with the
accepted system. Hence, the overall advantage of the MVB
model includes the shared responsibilities of individual
institutions for services and implementation of the
required standards and vocabulary that would foster data
sharing effortlessly.
Re-evaluation and Quality Control of CDEs
Annual re-evaluation and quality control of the CDEs of
the MVB will be conducted to determine which CDEs are
most useful for routine tissue and data collection and for
long-term update. If any desired CDE are found to be
poorly collected from a quality control or practical stand-
point, a process will be initiated to modify the data collec-
tion process through discussions with the cancer registrars
and data managers. The Coordinating Committee and the
Research Evaluation Panel will ensure that each participat-
ing institution will have a data manager responsible for
quality control and the re-evaluation of the resource as a
whole periodically to meet the needs of the mesothelioma
research community. The CDE sub-committee will be
charged to add new CDEs based on the needs of the
researchers and addition of new resource materials (e.g.,
Tissue Microarrays). Additionally, the Coordinating Com-
mittee will add dates to many of the CDE categories to
enable the examination of the timeline of major events
that may occur for each patient during his course of dis-
ease. This "event table" has resulted in a better picture and
assessment of the inter-related characteristics of patient
treatments and outcomes. Once the changes to the CDEs
are approved, the database will be modified accordingly.
The existing data will be re-mapped and migrated to the
revised CDE model.
Discussion
Advances in molecular biology and systems biology in
medicine have been the driving force that motivates devel-
opment of biorepositories to provide well characterized
and highly annotated tissue samples for basic science,
clinical, and translational research. Clinical annotation –
the association of demographic, epidemiologic, patho-
logic, treatment, progression, molecular and outcome
datasets – is central to the success of the repositories as
such annotation allows samples to be better matched to
the research question at hand and experimental results to
be better understood and verified [1-3]. To facilitate and
standardize clinical annotation of biospecimens and to
automate the process of annotation, the MVB project team
identified the NAACCR standard [23], and CAP cancer
protocol and ADASP guidelines for mesothelioma as the
well accepted, important and standardized sets of data
elements in their respective domains [24,28]. These stand-
ards consist of a series of reporting guidelines for diagnos-
tic pathology reports and outcome related descriptors for
the vast majority of human malignancies. Each CAP
guideline is comprised of checklists with the data ele-
ments to describe the gross as well as microscopic
attributes of the neoplasm including pathological staging
and perifocal reactions such as margins, angio – as well as
perineural invasion with specified valid values for each
data element that are important for clinical decision-mak-
ing and prognostication of individual cases.
The initial process of building a biospecimen resource
with high quality specimen annotation involves consider-
able time and commitment from domain experts from
various disciplines. Open discussions and input from all
potential parties with a stake in the outcome is crucial to
any such developmental work. The process of developing
the CDEs for the MVB has validated that this approach can
successfully lead to the implementation of robust human
mesothelioma-related CDEs that guide the collection of
high quality data for the research community. Clinicians
and Epidemiologists (MVB CDE subcommittee) were pri-
marily responsible for providing the foundation of data
elements as they reflected the current standard of informa-
tion used in patient care decisions, while attempting to
project at least five years into the future for additional data
that may become clinically significant. Likewise, research
scientists provided input on data elements that would be
crucial in the evaluation of current or proposed research
related to mesothelioma with respect to the diagnosis,
prognosis, and management of mesothelioma. Thus the
result was the creation of datasets that should provide
value to the end users, the research community, for years
to come. Additionally, it was very important to include in
CDE development the tissue bankers, data managers, and
cancer registrars who are the main data collectors for the
tissue banking resource. Their input on the types of data
and data descriptors available for collection proved to be
crucial in aggregating high-quality annotation data for the
biospecimens. Moreover, the definitions of the CDEs and
their associated descriptors need to be clearly understand-
able and consistent to all those who collect data. For
example, to collect quality data, the curators need to
understand 1) the fundamental and correct scientific def-
inition of the data element (i.e., date of diagnosis, his-
topathologic type, etc), 2) the way the data will be
collected (e.g. 11/2006 vs. Nov. 2006 vs. 11/06, etc), 3)
the consensus acceptable values or codes for the data ele-
ment (e.g., precise date of birth, not calculated from clin-
ical records where the "patient appears to be a wellBMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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developed 75 year old"), and 4) the acceptable data for-
mat for inclusion into the database (e.g., dates as "inte-
gers" not "character strings"). Through the use of ISO
compliance and accepted data standards the goal of col-
lecting annotation data of high quality was achievable.
The consensus approach used by MVB was critical to suc-
cessful CDE creation. Although the concept of formalized
metadata is reasonably straightforward, it has been rarely
integrated by clinical and research groups building data-
bases. This study of CDE development and deployment
shows that well developed CDEs can benefit comparative
research and in-depth analysis of data among multiple
institutions and studies. The only way in which informa-
tion from multiple databases can truly be shared and
made useful is through the careful use of unambiguous,
clearly defined, uniform and consistent metadata. Infor-
maticians and database developers provided the structural
link that brought the CDEs together in the database,
addressed technical issues, and provided guidance related
to implementation of the CDEs at local institutions. Fur-
thermore, having the ability to collect high-quality data
elements that have been agreed upon by a research evalu-
ation panel is crucial for the overall quality of quantitative
analysis of data. Collecting simple, yet uniform and com-
prehensive data annotations in a database for research
with various capabilities of collecting the data (manual
review of medical charts, cancer registry systems, and
interfaces to legacy systems), vastly increases the power of
research efforts and has the potential to identify the natu-
ral history, common trends and issues in cancer diagnosis
and management.
Conclusion
Recently, there have been an increasing number of local,
regional, national and international tissue banking efforts
that have promoted formation of large research consortia
and encourage these groups to share both tissue and data.
Currently, many tissue banks such as the CPCTR, PCABC,
caBIG, CBCTR, CHTN, CFR, SPOREs, and EDRN involve
multiple institutions [4,6-8,10-13,15,19-21]. These biore-
positories vary in their data collection and tissue collec-
tion methodologies and involve common malignancies.
However, the necessity for well-annotated tissues that can
be re-annotated with experimental data has driven many
of these multi-institutional collaborations to develop
standards of sharing data with other groups. In addition,
so far as human mesothelioma is concerned, there is no
such biorepository available with CDEs based upon
clearly defined, uniform and consistent metadata. Cur-
rently, the MVB CDEs are specifically related to the avail-
able mesothelioma tissue resources with multimodal
datasets. Publications resulting from the use of MVB tis-
sues will allow for the results to be correlated to or com-
pared with other studies using similar CDE standards.
Other initiatives such as the CPCTR, EDRN, PCABC, and
caBIG can perform follow-up studies by linking their
results to MVB-derived studies by using the common MVB
CDEs. This also allows for meta-analysis of data in a more
efficient and logical way across studies through the MVB
CDEs, resulting in improved statistical power and further
detailed analysis. Thus, expanding the MVB dataset by
combining tissue with molecular, genotype, gene expres-
sion, and image associated data will have remarkable
impact on cancer research community and will help in
understanding the genesis, evolution and progression of
disease through molecular validation and high-through-
put genomic and proteomic analysis, which will eventu-
ally reduce the burden and suffering of cancer.
Based on the experience of developing CDEs for the MVB,
the following sequential strategies can be recommended
for other research groups involved in future CDE develop-
ment efforts.
￿ Decide which CDEs the resource will need using a com-
mittee-driven consensus process that includes all major
stakeholders.
￿ Utilize as a starting point similar CDE initiatives already
developed by others and build upon their standards.
￿ Consult a variety of experts, including those that will be
directly collecting the data – particularly tissue bankers,
research nurse coordinators, cancer registrars and data
managers.
￿ Draft a CDE data dictionary which includes structured
data with precise data field definitions, attributes and
valid values.
￿ Modify or approve CDEs after discussions with all key
personnel and end users and build consensus among
them and any other external experts.
￿ Create corresponding data entry paper forms/data entry
interface to a central database.
￿ Implement CDEs.
￿ Test/Pilot phase: sharing of data with central database.
￿ Every year after initialization set accrual target and re-
evaluate and perform quality control measures on CDEs
and their values.
￿ Establish and continually develop quality assurance and
quality improvement protocols to fully develop the CDEs.BMC Cancer 2008, 8:91 http://www.biomedcentral.com/1471-2407/8/91
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